Johnson & Johnson
JNJ Healthcare Drug Manufacturers General
Johnson & Johnson’s revenue for fiscal 2025 (year ended December 2025) was $94.2 billion, up 6.05% from fiscal 2024. In the quarter to September 2026, revenue grew 5.86%, EPS was flat, free cash flow grew 154.8% and total debt fell 4.82%, each against the same quarter a year earlier. Member of the S&P 500 and Dow Jones; dividend growth for twenty-five consecutive years, revenue growth for three, operating cash flow growth for three; insiders bought in the last twelve months.
Follow JNJ
Johnson & Johnson (JNJ) EV/Sales
As of 16 October 2026, Johnson & Johnson (JNJ) trades at a EV/Sales of 6.4×. Over the past ten years it has ranged from 3.2× (August 2015) to 7.0× (September 2026); the current reading is higher than 97% of that period. That is above the Drug Manufacturers General industry median of 4.0× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 5.5× | 37.76% |
| FY2024 | 4.0× | (16.80%) |
| FY2023 | 4.8× | (18.83%) |
| FY2022 | 5.9× | 3.65% |
| FY2021 | 5.7× | 11.56% |
| FY2020 | 5.1× | 6.63% |
| FY2019 | 4.8× | 10.37% |
| FY2018 | 4.3× | (14.31%) |
| FY2017 | 5.1× | 22.33% |
| FY2016 | 4.1× | 11.92% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2026 | 6.6× | 2.66% |
| Jun 2026 | 6.4× | 2.26% |
| Mar 2026 | 6.3× | 14.13% |
| Dec 2025 | 5.5× | 8.33% |
| 43 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| PFE Pfizer Inc. compare | 3.5× |
| AZN AstraZeneca PLC compare | 4.6× |
| NVS Novartis AG compare | 5.8× |
| MRK Merck & Co., Inc. compare | 6.1× |
| JNJ Johnson & Johnson | 6.4× |
| GILD Gilead Sciences, Inc. compare | 7.1× |
| AMGN Amgen Inc. compare | 7.3× |
| ABBV AbbVie Inc. compare | 8.8× |
| LLY Eli Lilly and Company compare | 14.7× |
| Drug Manufacturers General industry median | 4.0× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)
More on JNJ
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement